CRANBURY, N.J.--(BUSINESS WIRE)--Jun. 28, 2024-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company...

Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on...

Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an...

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dravet Syndrome pipeline constitutes 12+ key companies continuously...

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

Wall Street closed lower on Friday, weighed down by tech and discretionary stocks.

U.S. stock ended mostly lower on Thursday, with the S&P 500 and Nasdaq ending their winning streak, as even industry bellwether NVIDIA gave up...

In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian stock markets. Here is a...